Clinical Trials Sponsored by Lyvgen Biopharma Holdings Limited

Total 7 results

Lyvgen Biopharma Holdings Limited

Recruiting

Phase 1 Trial of LVGN7409 (CD40 Agonist Antibody) as Single Agent and Combination Therapies in Advanced or Metastatic Malignancy

Cancer

United States
Lyvgen Biopharma Holdings Limited

Completed

Study of LVGN6051 (CD137 Agonist Antibody) in Advanced or Metastatic Malignancy

Cancer

China
Lyvgen Biopharma Holdings Limited

Not yet recruiting

A Study of LVGN6051 Combination Therapy in Patient With Head and Neck Squamous Cell Carcinoma (HNSCC)

Head and Neck Squamous Cell Carcinoma

China
Lyvgen Biopharma Holdings Limited

Recruiting

A Study of LVGN6051 Combined With Anlotinib in Patient With Soft Tissue Sarcoma

Soft Tissue Sarcoma

China
Lyvgen Biopharma Holdings Limited

Completed

Study of LVGN7409 (CD40 Agonist Antibody) in Locally Advanced, Metastatic or Recurrent/Refractory Malignancy

Cancer

China
Lyvgen Biopharma Holdings Limited
Merck Sharp & Dohme LLC

Recruiting

Phase 1 Trial of LVGN6051 as Single Agent and in Combination With Keytruda (Pembrolizumab) in Advanced or Metastatic Malignancy

Cancer

United States
M.D. Anderson Cancer Center
Lyvgen Biopharma Holdings Limited

Recruiting

Study of LVGN3616 and LVGN6051±LVGN7409 in Combination With Nab-Paclitaxel or Bevacizumab and Cyclophosphamide in Metastatic Solid Tumors

Gastric Cancer | Metastatic Uveal Melanoma | Metastatic Head and Neck Carcinoma | Metastatic Hepatocellular Carcinoma | Metastatic Ovarian Carcinoma | Metastatic Soft Tissue Sarcoma | Metastatic Esophageal | Metastatic HPV Related Solid Tumors

United States

Clinical Trials Sponsored by Lyvgen Biopharma Holdings Limited

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Saint Lucia

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations